Dedicated to Developing Novel Medicines for CNS Diseases

About Us

Committed to Advancing a New Generation of Oral Antidepressants

AV-101, an NMDA receptor glycine-binding (GlyB) site antagonist, is a new generation oral antidepressant drug candidate in Phase 2 development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard FDA-approved antidepressants, which consist primarily of commonly prescribed selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). Inspired by breakthrough clinical studies involving intravenous administration of a low dose of the FDA-approved anesthetic ketamine, orally-available AV-101's mechanism of action, and that of ketamine, is fundamentally differentiated from all FDA-approved antidepressants and atypical antipsychotics (such as aripiprazole) often administered with them, adjunctively.

VistaGen Therapeutics, Inc. Pipeline
What Makes AV-101 Different?

Going Above and Beyond Current Treatment Options

Focused on providing novel solutions for millions of depression patients with inadequate response to standard FDA-approved antidepressants.

Learn More About Ketamine and AV-101

Backed by an Experienced Leadership Team

Our highly experienced Management Team, Board of Directors, and CNS Clinical and Regulatory Advisory Board have a proven track record of developing innovative medicines to treat a wide range of CNS diseases and disorders.

Meet Our Team

Stock Information

View Detailed Stock Info
Day Range
52 Week Range

Corporate Presentation

For Investors

Email Updates

Be the first to receive news, events & updates Sign Up